AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 10 microg/kg
Number of subjects: 161
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 30 microg/kg
Number of subjects: 161
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 90 microg/kg
Number of subjects: 161
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (various doses)
Number of subjects: 161
Study 11123827 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of 400 mg of ferrous sulphate for 4 months
Number of subjects: 0
Study 11123827 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8741946 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (n = 26)
Number of subjects: 37
Study 8741946 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 37
Study 1528687 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐High self-efficacy condition
Number of subjects: 75
Study 1528687 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐Low self-efficacy condition
Number of subjects: 75
Study 1528687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐High self-efficacy condition
Number of subjects: 75
Study 1528687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐Low self-efficacy condition
Number of subjects: 75
Study 1528687 — intervention group
Group type: COMPARATOR
Intervention: Control (no biofeedback)
Number of subjects: 75
Study 3881376 — intervention group
Group type: EXPERIMENTAL
Intervention: Various radiation trials
Number of subjects: 800
Study 3881376 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant MOPP chemotherapy
Number of subjects: 800
Study 3881376 — intervention group
Group type: EXPERIMENTAL
Intervention: New mild adjuvant chemotherapy VBM (vinblastine, bleomycin, and methotrexate) with ABVD in combined modality and alternating regimens
Number of subjects: 800
Study 29930098 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy SRT
Number of subjects: 230
Study 29930098 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy SRT
Number of subjects: 230
Study 29930098 — intervention group
Group type: COMPARATOR
Intervention: Sham SRT
Number of subjects: 230
Study 30070576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile experience of warmth
Number of subjects: 0
Study 30070576 — intervention group
Group type: COMPARATOR
Intervention: Control temperatures
Number of subjects: 0
Study 27381935 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 0
Study 27381935 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control)
Number of subjects: 0
Study 24202298 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal geriatric inpatients (intervention group)
Number of subjects: 40
Study 24202298 — intervention group
Group type: COMPARATOR
Intervention: Nonsuicidal patients (control group)
Number of subjects: 40
Study 22126423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.03 µg/kg/day) - Monotherapy
Number of subjects: 30
Study 22126423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol and Risedronate (0.05 mg/kg/day) - Polytherapy
Number of subjects: 30
Study 22126423 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued medications)
Number of subjects: 30
Study 19825193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving anticipatory guidance via two modules of six fortnightly parent education and peer support group sessions, followed by six months of regular maintenance contact.
Number of subjects: 820
Study 19825193 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 820
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Strips
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐Drive D30
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: New Metal Strips
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Rotor
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: Profin
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: Profin and Ortho‐Strips (with polishing)
Number of subjects: 55
Study 18004908 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (with polishing)
Number of subjects: 55
Study 15109355 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 253
Study 15109355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 253
Study 15109355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 11913800 — intervention group
Group type: EXPERIMENTAL
Intervention: E 047/1 (1 mg kg(‐1) in pilot study, 2 mg kg(‐1) or 3 mg kg(‐1) bolus in randomized trial)
Number of subjects: 35
Study 11913800 — intervention group
Group type: COMPARATOR
Intervention: E 047/1 (2 mg kg(‐1) or 3 mg kg(‐1) bolus)
Number of subjects: 35
Study 9653596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone replacement with 17 beta‐estradiol and norethisterone
Number of subjects: 26
Study 9653596 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal women, n = 24)
Number of subjects: 26
Study 8595637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine 400 mg
Number of subjects: 240
Study 8595637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 240
Study 8595637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 2475016 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg twice daily)
Number of subjects: 55
Study 2475016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 824047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective pulmonary irradiation of 1500 rads administered to both lung fields
Number of subjects: 53
Study 824047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elective pulmonary irradiation)
Number of subjects: 53
Study 30247715 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit U exercises
Number of subjects: 60
Study 30247715 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 60
Study 27538247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 0
Study 26239241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered Internet-based intervention protocol (SII)
Number of subjects: 100
Study 26239241 — intervention group
Group type: COMPARATOR
Intervention: Medical usual care (MUC)
Number of subjects: 100
Study 23894900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe Vera gel
Number of subjects: 50
Study 23894900 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream
Number of subjects: 50
Study 21900631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-driven examinations
Number of subjects: 16
Study 21900631 — intervention group
Group type: COMPARATOR
Intervention: Screening examinations
Number of subjects: 16
Study 19947796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-specific group (n = 218)
Number of subjects: 916
Study 19947796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-general group (n = 234)
Number of subjects: 916
Study 19947796 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-trauma-exposed group (n = 464)
Number of subjects: 916
Study 19947796 — intervention group
Group type: COMPARATOR
Intervention: Non-trauma-exposed participants
Number of subjects: 916
Study 18042331 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 63
Study 18042331 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 63
Study 14747670 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake and reduced fat intake
Number of subjects: 393
Study 14747670 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 393
Study 10943268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study 9377833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfureous sulfate calcic water of the 'Pergoli' spring-Tabiano (Parma, Italy) (Group II: N. 10)
Number of subjects: 20
Study 9377833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aqua fontis) (Group I: N. 10)
Number of subjects: 20
Study 8381780 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral prefrontal lesion patients
Number of subjects: 24
Study 8381780 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 3770273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium infusion (calcium gluconate 36.3 mEq/5 h)
Number of subjects: 35
Study 3770273 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 35
Study 29080520 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile therapy
Number of subjects: 45
Study 27172423 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐day distributed bronchoscopy simulation practice
Number of subjects: 20
Study 27172423 — intervention group
Group type: COMPARATOR
Intervention: Weekly distributed bronchoscopy simulation practice
Number of subjects: 20
Study 25551337 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 motivational interviewing- and social network counseling-based personalized messages
Number of subjects: 72
Study 25551337 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (general health habits texting program)
Number of subjects: 72
Study 23902614 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery sympathetic denervation (RSD)
Number of subjects: 31
Study 23902614 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 31
Study 21650059 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐UPPP
Number of subjects: 64
Study 21650059 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-assisted H‐UPPP
Number of subjects: 64
Study 18342318 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-range PCR analysis of bacterial DNA signatures from aortic samples
Number of subjects: 20
Study 18342318 — intervention group
Group type: COMPARATOR
Intervention: Methodological controls
Number of subjects: 20
Study 18342318 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction analysis of bacterial sequences
Number of subjects: 20
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in spinal cord injury (5 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in traumatic brain injury (15 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in burn rehabilitation (12 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in spinal cord injury (26 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in traumatic brain injury (4 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in burn rehabilitation (2 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in spinal cord injury (34 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in traumatic brain injury (11 studies)
Number of subjects: 0
Study 16554683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in burn rehabilitation (5 studies)
Number of subjects: 0
Study 14627846 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C‐raclopride
Number of subjects: 10
Study 14627846 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (subchronic low dose)
Number of subjects: 10
Study 14627846 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (higher dose)
Number of subjects: 10
Study 14627846 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise simulations
Number of subjects: 10
Study 10442670 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiadhesion therapy directed towards phagocyte and endothelial adhesion molecules
Number of subjects: 0
Study 10442670 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of phagocyte activation
Number of subjects: 0
Study 8541425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 381
Study 8541425 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 381
Study 8541425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 381
Study 8541425 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 (historical controls)
Number of subjects: 381
Study 1835824 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 3 micrograms.kg‐1 with all pancuronium 1 min after sufentanil (control group)
Number of subjects: 57
Study 1835824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 3 micrograms.kg‐1 with 1 mg pancuronium 1 min before sufentanil and the balance of pancuronium 1 min after sufentanil (pretreated group)
Number of subjects: 57
Study 1835824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 3 micrograms.kg‐1 with all pancuronium mixed with sufentanil (mixed group)
Number of subjects: 57
Study 7282603 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g omega 3 fatty acids
Number of subjects: 52
Study 7282603 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 g omega 3 fatty acids
Number of subjects: 52
Study 7282603 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.1 g omega 3 fatty acids
Number of subjects: 52
Study 7282603 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.2 g omega 3 fatty acids
Number of subjects: 52
Study 29368994 — intervention group
Group type: EXPERIMENTAL
Intervention: Message to avoid antipsychotic medications
Number of subjects: 158
Study 29368994 — intervention group
Group type: COMPARATOR
Intervention: Managerial oversight
Number of subjects: 158
Study 29368994 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual facility antipsychotic prevalence
Number of subjects: 158
Study 29368994 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid antipsychotics message
Number of subjects: 158
Study 28526947 — intervention group
Group type: EXPERIMENTAL
Intervention: UC patients with TCN2 (rs1801198) genotypes
Number of subjects: 527
Study 28526947 — intervention group
Group type: EXPERIMENTAL
Intervention: UC patients
Number of subjects: 527
Study 28526947 — intervention group
Group type: EXPERIMENTAL
Intervention: HHcy and folate deficiency
Number of subjects: 527
Study 26224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Short retention interval (RI)
Number of subjects: 480
Study 26224752 — intervention group
Group type: COMPARATOR
Intervention: Long retention interval (RI)
Number of subjects: 480
Study 26224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward prompts
Number of subjects: 480
Study 26224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-name prompts
Number of subjects: 480
Study 26224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Open prompts
Number of subjects: 480
Study 26224752 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse prompts
Number of subjects: 480
Study 24122767 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab with 2 mg/kg conatumumab
Number of subjects: 202
Study 24122767 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab with 10 mg/kg conatumumab
Number of subjects: 202
Study 24122767 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab with placebo
Number of subjects: 202
Study 20049495 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic matrix and wooden wedge
Number of subjects: 23
Study 20049495 — intervention group
Group type: COMPARATOR
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study 18758971 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation pharmacotherapy
Number of subjects: 263
Study 18758971 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence to quit smoking
Number of subjects: 263
Study 16862288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral T3, 25 microg three times/day, initiated 24 h before surgery and maintained for 48 h
Number of subjects: 18
Study 16862288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NT group)
Number of subjects: 18
Study 15561516 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment for 4 weeks
Number of subjects: 91
Study 15561516 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (continued previous headache treatment)
Number of subjects: 91
Study 15561516 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment
Number of subjects: 91
Study 15561516 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 91
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on paper in their mother tongue
Number of subjects: 114
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on screen in their mother tongue
Number of subjects: 114
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on paper in English
Number of subjects: 114
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on screen in English
Number of subjects: 114
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading in their mother tongue (combined)
Number of subjects: 114
Study 12555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading in English (combined)
Number of subjects: 114
Study 11995034 — intervention group
Group type: EXPERIMENTAL
Intervention: NLA general anaesthesia
Number of subjects: 45
Study 11995034 — intervention group
Group type: COMPARATOR
Intervention: Spinal analgesia
Number of subjects: 45
Study 9050617 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy for chronic pelvic pain
Number of subjects: 80
Study 9050617 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy for tubal sterilization (Control)
Number of subjects: 80
Study 9050617 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided paracolic adhesions
Number of subjects: 80
Study 2202093 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid plus dipyridamole
Number of subjects: 2500
Study 2202093 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 2500
Study 318894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg oral dose
Number of subjects: 0
Study 318894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6753769 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 32
Study 6753769 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 32
Study 30461557 — intervention group
Group type: COMPARATOR
Intervention: diet + exercise
Number of subjects: 439
Study 30461557 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 439
Study 30461557 — intervention group
Group type: EXPERIMENTAL
Intervention: diet
Number of subjects: 439
Study 30461557 — intervention group
Group type: EXPERIMENTAL
Intervention: weight loss maintenance
Number of subjects: 439
Study 29515001 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based blood pressure monitoring device
Number of subjects: 62
Study 29515001 — intervention group
Group type: COMPARATOR
Intervention: Finger cuff device (control)
Number of subjects: 62
Study 26720622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with flexibility in duty hour policies (ACGME waiver allowing deviation from current standards)
Number of subjects: 118
Study 26720622 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm adhering to current ACGME resident duty hour standards
Number of subjects: 118
Study 26720622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with flexibility in duty hour policies
Number of subjects: 118
Study 25291116 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01 delivered via slow-release vaginal tablets (400 million live cells per dose) for 7 consecutive nights followed by 1 tablet every 3 nights for 3 weeks and then 1 tablet per week for long-term maintenance.
Number of subjects: 34
Study 25291116 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no significant differences recorded at any time).
Number of subjects: 34
Study 21865044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 244
Study 21865044 — intervention group
Group type: COMPARATOR
Intervention: External breast radiotherapy (EBRT)
Number of subjects: 244
Study 20814326 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores rated by the physician in charge (PIC) using the Positive and Negative Syndrome Scale (PANSS).
Number of subjects: 36
Study 20814326 — intervention group
Group type: COMPARATOR
Intervention: Scores rated by non-PIC psychiatrists using the PANSS.
Number of subjects: 36
Study 20814326 — intervention group
Group type: COMPARATOR
Intervention: Scores rated by one of the non-PIC physicians using the PANSS.
Number of subjects: 36
Study 17932848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol 0.25%-betamethasone 0.13% gel three times a day (Group 1)
Number of subjects: 142
Study 17932848 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%-dexamethasone 0.1% eyedrops four times a day (Group 2)
Number of subjects: 142
Study 16249353 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m² i.v. day 1) and topotecan (1.5 mg/m² i.v. days 1, 2, and 3) every 21 days
Number of subjects: 120
Study 16249353 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m² i.v. day 1), carboplatin (AUC 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1-10) every 21 days
Number of subjects: 120